Linked Life Data

21501447

Source:http://linkedlifedata.com/resource/pubmed/id/21501447

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:dateCreated
2011-4-19
pubmed:abstractText
Meningococcal meningitis is a major cause of disease worldwide, with frequent epidemics particularly affecting an area of sub-Saharan Africa known as the "meningitis belt". Neisseria meningitidis group A (MenA) is responsible for major epidemics in Africa. Recently W-135 has emerged as an important pathogen. Currently, the strategy for control of such outbreaks is emergency use of meningococcal (MC) polysaccharide vaccines, but these have a limited ability to induce herd immunity and elicit an adequate immune response in infant and young children. In recent times initiatives have been taken to introduce meningococcal conjugate vaccine in these African countries. Currently there are two different types of MC conjugate vaccines at late stages of development covering serogroup A and W-135: a multivalent MC conjugate vaccine against serogroup A,C,Y and W-135; and a monovalent conjugate vaccine against serogroup A. We aimed to perform a structured assessment of these emerging meningococcal vaccines as a means of reducing global meningococcal disease burden among children under 5 years of age.
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:issn
1471-2458
pubmed:author
pubmed:issnType
Electronic
pubmed:volume
11 Suppl 3
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
S29
pubmed:meshHeading
pubmed:year
2011
pubmed:articleTitle
An evaluation of emerging vaccines for childhood meningococcal disease.
pubmed:affiliation
Centre for Population Health Sciences, Global Health Academy, The University of Edinburgh, UK.
pubmed:publicationType
Journal Article, Review, Research Support, Non-U.S. Gov't, Evaluation Studies